Mathai Mammen SVP at Theravance to speak at Modern Drug Summit Oct 20 CA-SF

Mathai Mammen, Senior Vice President of Research and Early Clinical Development at Theravance will give a plenary keynote presentation on “Multivalent Design in Drug Discovery” at the 6th Modern Drug Discovery and Development Summit to be held this year in San Francisco, CA on Oct 20-22, 2010 by GTCbio. Theravance leverages Multivalent Design to install useful molecular features, such as high potency, high selectivity, duration of action, and activity at a second biological target to create novel and highly differentiated medicines. Examples of drugs and candidates in Development created by the use of Multivalent Design include the following: VIBATIVTM (telavancin) an antibiotic with two complementary pharmacologies approved in 2009 for the treatment of adult patients with complicated skin and skin structure infections; TD-1792, a second antibiotic with two different complementary pharmacologies that has completed a Phase 2 study in complicated skin and skin structure infections; and TD-5959, which as a single molecule acts to both agonize the 2 adrenoreceptor and antagonize the M3 muscarinic receptor, has completed Phase 2a studies in Chronic Obstructive Pulmonary Disease. The discovery and characterization of these compounds will be described to illustrate the utility, depth and breadth of Multivalent Design in Drug Discovery

[USPRwire, Sun Aug 22 2010] Mathai Mammen, Senior Vice President ofResearch and Early Clinical Development at Theravance to give plenary keynote presentation at GTCbio’s 6th Modern Drug Discovery and Development Summit taking place on October 20-22, 2010 in San Francisco, CA.

Dr. Mammen will give a presentation on “Multivalent Design in Drug Discovery” at the 6th Modern Drug Discovery and Development Summit taking place on October 20-22, 2010 in San Francisco, CA by GTCbio. Theravance leverages Multivalent Design to install useful molecular features, such as high potency, high selectivity, duration of action, and activity at a second biological target to create novel and highly differentiated medicines. Examples of drugs and candidates in Development created by the use of Multivalent Design include the following: VIBATIVTM (telavancin) an antibiotic with two complementary pharmacologies approved in 2009 for the treatment of adult patients with complicated skin and skin structure infections; TD-1792, a second antibiotic with two different complementary pharmacologies that has completed a Phase 2 study in complicated skin and skin structure infections; and TD-5959, which as a single molecule acts to both agonize the 2 adrenoreceptor and antagonize the M3 muscarinic receptor, has completed Phase 2a studies in Chronic Obstructive Pulmonary Disease. The discovery and characterization of these compounds will be described to illustrate the utility, depth and breadth of Multivalent Design in Drug Discovery.

Mathai Mammen, co-founded Theravance in 1996 on the basis of his doctoral work in chemistry, aiming to define a new and useful approach to the creation of medicines called Multivalent Design. He is responsible for Early Clinical Development, has initiated and led several major programs at Theravance and served in various senior level positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Department.

The Theravance team has to date used its proprietary approach to discover twenty-one candidates for progression into human clinical trials. They have partnered several of their clinical candidates with three major pharmaceutical companies, GlaxoSmithKline plc, Astellas Pharma, Inc., and Astra Zeneca.

Also presenting at the 6th Modern Drug Summit are prestigious organizations including Abbott, Amgen, AstraZeneca, Bayer Healthcare, Eli Lilly, FDA, GE Global Research, Genentech, Genzyme, Harvard, Human Genome Sciences, Merck, NCI / NIH, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Siemens, Stanford, Theravance, UC San Francisco, UC Berkeley and other leaders in the industry.

This 6th Modern Drug Discovery and Development Summit includes a plenary keynote presentation and four concurrent tracks: The 4th Annual Advances in Stem Cell Discovery and Development, 5th Annual Biological Therapeutics Research and Development, 2nd Annual Cancer Targets and Therapeutics and 4th Annual Biomarker Discovery and Development. For more information, visit www.gtcbio.com